Rukobia is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced adult patients with multidrug-resistant HIV-1 infection who are eligible for, and have been on, antiretroviral therapy.
What is Rukobia used for?
Rukobia, also known by its chemical name Fostemsavir, is an HIV-1 integrase strand transfer inhibitor. It works by preventing the HIV virus from integrating into the host cell's DNA, a crucial step in the virus's replication cycle [1]. This mechanism helps to suppress viral load and allow the immune system to recover.
Who is Rukobia for?
The FDA approval specifically targets adult patients who have been on antiretroviral therapy for a significant period and have developed resistance to multiple HIV medications. This means Rukobia is intended for individuals with limited treatment options remaining due to the virus's ability to evade existing drugs [1].
How does Rukobia work?
Rukobia functions by blocking the action of HIV-1 integrase, an enzyme essential for the virus to insert its genetic material into the DNA of human cells. By inhibiting this enzyme, Rukobia halts the replication process of the virus [1].
When was Rukobia approved?
Rukobia received FDA approval on July 2, 2020 [1].
What are the potential side effects of Rukobia?
Common side effects associated with Rukobia include diarrhea, nausea, and fatigue. More serious potential side effects may include liver problems, particularly in patients with pre-existing liver conditions like hepatitis B or C [1].
Are there any drug interactions with Rukobia?
Rukobia can interact with certain other medications. It is important for patients to inform their healthcare provider about all prescription drugs, over-the-counter medicines, and supplements they are taking to avoid potentially harmful interactions [1].
How is Rukobia administered?
Rukobia is an oral medication taken twice daily with or without food [1].
What is the dosage of Rukobia?
The recommended dosage for Rukobia is 600 mg taken orally twice a day [1].
Does Rukobia have any patent information?
Information regarding the patent status and expiration dates for Rukobia and its active ingredient, Fostemsavir, can be found on resources like DrugPatentWatch.com [2]. Patents play a role in determining when generic versions of a drug may become available.
What are the clinical trial results for Rukobia?
Clinical trials supporting Rukobia's approval demonstrated its efficacy in reducing viral load and increasing CD4+ cell counts in heavily treatment-experienced patients. For instance, the MODEST study showed significant viral load reduction in participants receiving Rukobia in combination with an optimized background regimen [1].
What are the regulatory considerations for Rukobia?
The FDA's approval was based on a thorough review of clinical data demonstrating the drug's safety and effectiveness for its indicated patient population. Ongoing pharmacovigilance monitors for any new safety concerns that may arise post-approval.
What is the commercial availability of Rukobia?
Rukobia is manufactured by ViiV Healthcare. It is available through prescription and is typically covered by most insurance plans, though patient assistance programs may be available for those facing financial challenges [1].
Sources:
1. U.S. Food and Drug Administration (FDA) - Information on Rukobia (Fostemsavir) approval and prescribing information.
2. DrugPatentWatch.com